EICBPI 2027 supports responsible dissemination of biotechnology, pharmaceutical, translational, clinical, manufacturing and innovation research. Accepted conference contributions may be included in the EICBPI 2027 conference proceedings at no publication charge from the conference. Selected high-quality papers may also be recommended for consideration by partner journals, subject to the journal's own scope, editorial assessment, peer review and final decision.
Publication is optional, event-dependent, and always subject to scope fit, editorial review, and applicable policies.
There is no publication fee charged by EICBPI 2027 for publication in the conference proceedings. Eligible accepted abstracts, summaries or papers may be included in the official conference proceedings subject to the conference's formatting, originality, ethics and editorial requirements.
Authors do not need to pay an additional publication-support fee or proceedings publication fee to EICBPI 2027. Conference registration and proceedings publication are treated separately from any external journal or publisher charges.
In addition, selected high-quality papers may be recommended for consideration by partner journals after the conference. Such recommendation does not guarantee publication. Journal publication remains subject to the journal's own scope, peer-review process, editorial policies, revision requirements and final editorial decision.
If a partner journal or publisher applies an article processing charge, open-access fee, tax, page charge or other publisher-side fee, that charge is independent of EICBPI 2027 and is governed directly by the relevant journal or publisher.
EICBPI 2027 offers a free conference proceedings pathway and, for selected high-quality work, possible recommendation to relevant partner journals for independent editorial consideration.
Accepted and eligible conference contributions may be included in the official EICBPI 2027 proceedings.
An international peer-reviewed open-access journal covering biotechnology and biosciences. Selected high-quality papers from EICBPI 2027 may be recommended for Special Issue or other relevant editorial consideration, subject to journal scope, peer review and editorial decision.
Visit Journal Page →Selected papers relevant to biotechnology and bioengineering may be recommended for editorial consideration. Relevant areas may include cell, tissue and organoid culture; disease models and therapeutics; synthetic biology and nanobiotechnology; metabolic engineering; bioenergy and bioprocesses; industrial processes; and plant and medical biotechnology. Any recommendation remains subject to Wiley's journal scope, peer-review process, editorial policies and final decision.
Visit Journal Page →Submit an abstract, receive acceptance and present your work at the conference.
Eligible contributions may be included in the conference proceedings at no publication charge from EICBPI 2027.
Selected high-quality papers may be recommended for consideration by an appropriate partner journal.
Authors submit to the journal and follow its independent peer-review, revision and editorial decision process.
All submitted content must be original and must not infringe copyright, intellectual property rights, confidentiality obligations, or third-party permissions.
Executive Congresses does not support plagiarism, duplicate submission, fabricated data, ghostwriting, misleading claims, or unethical research and reporting conduct.
Where relevant, contributors may be asked to disclose conflicts of interest, approvals, permissions, or consent-related documentation.
Because EICBPI 2027 includes research and industry-facing participation, contributors should avoid including proprietary, confidential, regulated, or commercially sensitive information unless expressly cleared for disclosure.
Some senior-level discussions may be suitable only for non-attributable summaries or high-level synthesized outcomes, rather than formal publication.
Publication suitability is assessed on quality, originality, ethics, disclosure appropriateness, scope and editorial relevance.
No. EICBPI 2027 does not charge authors a separate fee for publication in the conference proceedings.
No. Journal publication is completely separate from conference participation. Selected high-quality papers may be recommended, but the journal independently decides whether to send a manuscript for review, request revisions, accept or decline it.
The current publication partners shown on this page are Biotech (MDPI) and Biotechnology Journal (Wiley Online Library).
Yes. Any journal or publisher-side APC, open-access fee, tax, page charge or related fee is independent of EICBPI 2027 and is governed directly by that journal or publisher. The conference's free proceedings policy does not waive external publisher charges.
Contact our team if you need clarification about conference proceedings, partner-journal recommendations, manuscript suitability or the publication process.